Blanc, Jean-Frédéric
Khemissa, Faiza
Bronowicki, Jean-Pierre
Monterymard, Carole
Perarnau, Jean-Marc
Bourgeois, Vincent
Obled, Stéphane
Abdelghani, Meher Ben
Mabile-Archambeaud, Isabelle
Faroux, Roger
Seitz, Jean-François
Locher, Christophe
Senellart, Hélène
Villing, Anne-Laure
Audemar, Franck
Costentin, Charlotte
Deplanque, Gaël
Manfredi, Sylvain
Edeline, Julien http://orcid.org/0000-0002-8289-7741
,
Boucher, Evelyne
Talarmin, Marie
Le Sourd, Samuel
Vergniol, Julien
Gagnaire, Alice
Bedenne, Laurent
Jouve, Jean-Louis
Hillon, Patrick
Lepage, Côme
Minello, Anne
Barraud, Hélène
Lecomte, Thierry
Barbieux, Jean-Pierre
Wolff, Patrice
Phoutthasang, Valérie
Belletier, Christine
Archambeaud, Isabelle
Budnik, Tamara Matysiak
Schnee, Matthieu
Duluc, Muriel
Monnereau, Emmanuelle Norguet
Bennouna, Jaafar
Hiret, Sandrine
Gatineau, Michel
Ramdani, Mohamed
Le Bricquir, Yann
Ganne-Carrie, Nathalie
Bourcier, Valérie
Pilette, Christophe
Dauvois, Barbara
Baconnier, Mathieu
Michel, Pierre
Thevenet, Philippe
Cosme-Gassmann, Hélène
Habersetzer, François
Coltescu, Camélia
Pauwels, Mathieu
Brissonneau, Sophie Nahon
Egreteau, Joëlle
Desrame, Jérôme
Auby, Dominique
Texereau, Patrick
Etienne, Pierre-Luc
Dourthe, Louis-Marie
Tazi, Youssef
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
https://doi.org/10.1007/s12072-020-10120-3
Funding for this research was provided by:
institut national du cancer (PHRC10_04-02)
Sanofi Pasteur
Article History
Received: 29 September 2020
Accepted: 2 December 2020
First Online: 9 January 2021
Compliance with ethical standards
:
: Jean-Frédéric Blanc received honoraria from Bayer, Ipsen, Roche, outside the submitted work. Jean-Pierre Bronowicki received honoraria from Bayer outside the submitted work. Julien Edeline received honoraria from Roche, Bayer, Eisai, Ipsen, MSD, BMS, AstraZeneca, BTG, Amgen, Beigene, outside the submitted work.
: This study was approved by an ethic committee and conducted under the principles of the declaration of Helsinki. The trial was approved by the Ethics Committee ‘Comité de protection des personnes Sud Ouest et Outre Mer III’ on the 23/02/2020.
: All patients provided written informed consent.